Ahead of the House Ways and Means Committee hearing titled “More Cures for More Patients: Overcoming Pharmaceutical Barriers,” ERIC sent a letter to Chairman Doggett and Ranking Member Nunes commending lawmakers’ efforts to lower drug costs by addressing abuses that hinder competition and drive up prescription drug costs for patients.
Some of these abuses include:
- Drug “coupon” arrangements that steer patients to expensive drugs and hinder generic and biosimilar competition
- Rebate and discount structures that cause drug formularies to be based on metrics other than value for patients
- Patent evergreening and other methods of extending exclusivity that negate incentives to innovate new cures
- Undermining of medical management techniques designed to help patients control costs; and more.
Click here to read ERIC’s letter.